Abstract
Plasmodium falciparum is the causative agent of the most serious form of malaria. Although a combination of control measures has significantly limited malaria morbidity and mortality in the last few years, it is generally agreed that sustained control or even eradication will require additional tools including an effective malaria vaccine. Merozoite surface protein 4, MSP4, which is present during the asexual stage of P. falciparum, is a recognized target that would be useful in a subunit vaccine against blood stages of malaria. Falciparum malaria is most prevalent in developing countries, and this in turn leads to a requirement for safe, low-cost vaccines. We have attempted to utilize the nonpathogenic, gram-positive organism Bacillus subtilis to produce PfMSP4. PfMSP4 was secreted into the culture medium at a yield of 4.5 mg/L. Characterization studies including SDS-PAGE, mass spectrometry, and N-terminal sequencing indicated that the B. subtilis expression system secreted a full length PfMSP4 protein compared to a truncated version in Escherichia coli. Equivalent amounts of purified B. subtilis and E. coli-derived PfMSP4 were used for immunization studies, resulting in statistically significant higher mean titer values for the B. subtilis-derived immunogen. The mouse antibodies raised against B. subtilis produced PfMSP4 that were reactive to parasite proteins as evidenced by immunoblotting on parasite lysate and indirect immunofluorescence assays of fixed parasites. The B. subtilis expression system, in contrast to E. coli, expresses higher amounts of full length PfMSP4 products, decreased levels of aggregates, and allows the development of simplified downstream processing procedures.
Similar content being viewed by others
References
Anders RF, Adda CG, Foley M, Norton RS (2010) Recombinant protein vaccines against the asexual blood-stages of Plasmodium falciparum. Hum Vaccin 6(1):39–53
Billiau A, Matthys P (2001) Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J Leukoc Biol 70(6):849–860
Black CG, Wu T, Wang L, Hibbs AR, Coppel RL (2001) Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. Mol Biochem Parasitol 114(2):217–226
Black CG, Barnwell JW, Huber CS, Galinski MR, Coppel RL (2002) The Plasmodium vivax homologues of merozoite surface proteins 4 and 5 from Plasmodium falciparum are expressed at different locations in the merozoite. Mol Biochem Parasitol 120(2):215–224
Coppel RL (2009) Vaccinating with the genome: a Sisyphean task? Trends Parasitol 25(5):205–212
de Silva HD, Saleh S, Kovacevic S, Wang L, Black CG, Plebanski M, Coppel RL (2011) The antibody response to Plasmodium falciparum merozoite surface protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes. Malar J 10:266
Ellis RD, Sagara I, Doumbo O, Wu Y (2010) Blood stage vaccines for Plasmodium falciparum: current status and the way forward. Hum Vaccin 6(8):627–634
Gilson PR, Nebl T, Vukcevic D, Moritz RL, Sargeant T, Speed TP, Schofield L, Crabb BS (2006) Identification and stoichiometry of glycosylphosphatidylinositol-anchored membrane proteins of the human malaria parasite Plasmodium falciparum. Mol Cell Proteomics 5(7):1286–1299
Goschnick MW, Black CG, Kedzierski L, Holder AA, Coppel RL (2004) Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. Infect Immun 72(10):5840–5849
Greenwood BM, Bojang K, Whitty CJ, Targett GA (2005) Malaria. Lancet 365(9469):1487–1498
Halling SM, Sanchez-Anzaldo FJ, Fukuda R, Doi RH, Meares CF (1977) Zinc is associated with the beta subunit of DNA-dependent RNA polymerase of Bacillus subtilis. Biochemistry 16(13):2880–2884
Kedzierski L, Black CG, Coppel RL (2000) Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge. Infect Immun 68(10):6034–6037
Kedzierski L, Black CG, Goschnick MW, Stowers AW, Coppel RL (2002) Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. Infect Immun 70(12):6606–6613
Kenney JS, Hughes BW, Masada MP, Allison AC (1989) Influence of adjuvants on the quantity, affinity, isotype and epitope specificity of murine antibodies. J Immunol Methods 121(2):157–166
Kunst F, Ogasawara N, Moszer I, Albertini AM, Alloni G, Azevedo V, Bertero MG, Bessieres P, Bolotin A, Borchert S, Borriss R, Boursier L, Brans A, Braun M, Brignell SC, Bron S, Brouillet S, Bruschi CV, Caldwell B, Capuano V, Carter NM, Choi SK, Codani JJ, Connerton IF, Cummings NJ, Daniel RA, Denizot F, Devine KM, Dusterhoft A, Ehrlich SD, Emmerson PT, Entian KD, Errington J, Fabret C, Ferrari E, Foulger D, Fritz C, Fujita M, Fujita Y, Fuma S, Galizzi A, Galleron N, Ghim SY, Glaser P, Goffeau A, Golightly EJ, Grandi G, Guiseppi G, Guy BJ, Haga K, Haiech J, Harwood CR, Henaut A, Hilbert H, Holsappel S, Hosono S, Hullo MF, Itaya M, Jones L, Joris B, Karamata D, Kasahara Y, Klaerr-Blanchard M, Klein C, Kobayashi Y, Koetter P, Koningstein G, Krogh S, Kumano M, Kurita K, Lapidus A, Lardinois S, Lauber J, Lazarevic V, Lee SM, Levine A, Liu H, Masuda S, Mauel C, Medigue C, Medina N, Mellado RP, Mizuno M, Moestl D, Nakai S, Noback M, Noone D, O’Reilly M, Ogawa K, Ogiwara A, Oudega B, Park SH, Parro V, Pohl TM, Portetelle D, Porwollik S, Prescott AM, Presecan E, Pujic P, Purnelle B, Rapoport G, Rey M, Reynolds S, Rieger M, Rivolta C, Rocha E, Roche B, Rose M, Sadaie Y, Sato T, Scanlan E, Schleich S, Schroeter R, Scoffone F, Sekiguchi J, Sekowska A, Seror SJ, Serror P, Shin BS, Soldo B, Sorokin A, Tacconi E, Takagi T, Takahashi H, Takemaru K, Takeuchi M, Tamakoshi A, Tanaka T, Terpstra P, Tognoni A, Tosato V, Uchiyama S, Vandenbol M, Vannier F, Vassarotti A, Viari A, Wambutt R, Wedler E, Wedler H, Weitzenegger T, Winters P, Wipat A, Yamamoto H, Yamane K, Yasumoto K, Yata K, Yoshida K, Yoshikawa HF, Zumstein E, Yoshikawa H, Danchin A (1997) The complete genome sequence of the Gram-positive bacterium Bacillus subtilis. Nature 390(6657):249–256
Ling LF, Zi Rong X, Wei Fen L, Jiang Bing S, Ping L, Chun Xia H (2007) Protein secretion pathways in Bacillus subtilis: implication for optimization of heterologous protein secretion. Biotechnol Adv 25(1):1–12
Ma C, Wang L, Webster DE, Campbell AE, Coppel RL (2012) Production, characterisation and immunogenicity of a plant-made Plasmodium antigen—the 19 kDa C-terminal fragment of Plasmodium yoelii merozoite surface protein 1. Appl Microbiol Biotechnol 94(1):151–161
Magalhaes PO, Lopes AM, Mazzola PG, Rangel-Yagui C, Penna TC, Pessoa A Jr (2007) Methods of endotoxin removal from biological preparations: a review. J Pharm Pharm Sci 10(3):388–404
Marshall VM, Silva A, Foley M, Cranmer S, Wang L, McColl DJ, Kemp DJ, Coppel RL (1997) A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. Infect Immun 65(11):4460–4467
Mehlin C, Boni E, Buckner FS, Engel L, Feist T, Gelb MH, Haji L, Kim D, Liu C, Mueller N, Myler PJ, Reddy JT, Sampson JN, Subramanian E, Van Voorhis WC, Worthey E, Zucker F, Hol WGJ (2006) Heterologous expression of proteins from Plasmodium falciparum: results from 1000 genes. Mol Biochem Parasitol 148(2):144–160
Moks T, Abrahmsen L, Holmgren E, Bilich M, Olsson A, Pohl G, Sterky C, Hultberg H, Josephson S (1987) Expression of human insulin-like growth factor I in bacteria: use of optimized gene fusion vectors to facilitate protein purification. Biochemistry 26(17):5239–5244
Nguyen HD, Phan TT, Schumann W (2011) Analysis and application of Bacillus subtilis sortases to anchor recombinant proteins on the cell wall. AMB Express 1(1):22
Porath J, Carlsson J, Olsson I, Belfrage G (1975) Metal chelate affinity chromatography, a new approach to protein fractionation. Nature 258(5536):598–599
Sanders PR, Kats LM, Drew DR, O’Donnell RA, O’Neill M, Maier AG, Coppel RL, Crabb BS (2006) A set of glycosylphosphatidyl inositol-anchored membrane proteins of Plasmodium falciparum is refractory to genetic deletion. Infect Immun 74(7):4330–4338
Simonen M, Palva I (1993) Protein secretion in Bacillus species. Microbiol Rev 57(1):109–137
Wang L, Black CG, Marshall VM, Coppel RL (1999) Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. Infect Immun 67(5):2193–2200
Wang L, Richie TL, Stowers A, Nhan DH, Coppel RL (2001) Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun 69(7):4390–4397
Wang L, Marshall VM, Coppel RL (2002) Limited polymorphism of the vaccine candidate merozoite surface protein 4 of Plasmodium falciparum. Mol Biochem Parasitol 120(2):301–303
Wang L, Webster DE, Campbell AE, Dry IB, Wesselingh SL, Coppel RL (2008) Immunogenicity of Plasmodium yoelii merozoite surface protein 4/5 produced in transgenic plants. Int J Parasitol 38(1):103–110
Westers L, Westers H, Quax WJ (2004) Bacillus subtilis as cell factory for pharmaceutical proteins: a biotechnological approach to optimize the host organism. Biochim Biophys Acta 1694(1–3):299–310
WHO (2012) World Health Organization, World Malaria Report 2012 (World Health Organization, Geneva, 2012)
Wilms B, Hauck A, Reuss M, Syldatk C, Mattes R, Siemann M, Altenbuchner J (2001) High-cell-density fermentation for production of l-N-carbamoylase using an expression system based on the Escherichia coli rhaBAD promoter. Biotechnol Bioeng 73(2):95–103
Wong SL (1995) Advances in the use of Bacillus subtilis for the expression and secretion of heterologous proteins. Curr Opin Biotechnol 6(5):517–522
Zweers JC, Barak I, Becher D, Driessen AJ, Hecker M, Kontinen VP, Saller MJ, Vavrova L, van Dijl JM (2008) Towards the development of Bacillus subtilis as a cell factory for membrane proteins and protein complexes. Microb Cell Factories 7:10
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chittibabu, G., Ma, C., Netter, H.J. et al. Production, characterization, and immunogenicity of a secreted form of Plasmodium falciparum merozoite surface protein 4 produced in Bacillus subtilis . Appl Microbiol Biotechnol 98, 3669–3678 (2014). https://doi.org/10.1007/s00253-013-5275-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00253-013-5275-1